The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer.

"the datasets generated and analyzed during the current study are available in the geo repository (code gse188315)."

"Declarations Competing interestsThe authors declare no competing interests. Ethics approval and consent to partecipateAnimal Experiments were performed according to the Italian laws (D.L. 116/92 and following additions) that enforce the EU 86/109 Directive and were approved by the local animal ethics committee (OPBA, Organismo Preposto al Benessere degli Animali, Università degli Studi di Brescia, Italy). Breast cancer samples were obtained from the institutional biobank of the University Hospital Liege Belgium, following the approval of the institutional ethical committee (reference number 2009/69). According to Belgian law, patients obtained the information that the residual material could be used for research purpose and the consent is presumed as long as the patient does not oppose (opting-out). Consent for publicationNot applicable. Competing interests The authors declare no competing interests."

"Funding R.R. was supported by Associazione Italiana Ricerca sul Cancro (AIRC IG 2019 – ID.23151), M.P. was supported by Associazione Italiana Ricerca sul Cancro (AIRC IG 2019 – ID. 18493); E.G., S.R. and F.M. were supported by Fondazione Umberto Veronesi fellowships."